Is Abbott Laboratories' (NYSE:ABT) Recent Stock Performance Influenced By Its Financials In Any Way?
Most readers would already know that Abbott Laboratories' (NYSE:ABT) stock increased by 7.2% over the past three months. We wonder if and what role the company's financials play in that price change ...
UK regulator flags concerns and remedies for sale of baby formula
Britain's competition watchdog flagged concerns and potential solutions regarding the distribution of infant formulas on ...
Litigators of the Week: After Two Big Wins for Plaintiffs, a Defense Verdict for Infant Formula Makers
Juries hit Mead Johnson and Abbott Laboratories with verdicts of $60 million and $495 million respectively earlier this year ...
China Internet Information Center3d
Global medical giants tapping Chinese market at import expo
With an array of new medicines and medical devices on display, global medical companies are looking to tap further into the ...
Zacks.com on MSN6d
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...
Lawyer Monthly6d
Missouri Judge Bars Kirkland Partner from Abbott Infant Formula Trial
Missouri Judge Sanctions Kirkland Lawyer, Barring Him from Abbott Infant Formula Trial Over Alleged Misconduct in High-Stakes NEC Case ...
Abbott price target raised to $149 from $143 at Barclays
Barclays analyst Matt Miksic raised the firm’s price target on Abbott (ABT) to $149 from $143 and keeps an Overweight rating ...
Sinar Daily on MSN6d
Abbott’s #StartsWithYou campaign: Empowering Malaysians to manage diabetes with Glucerna
Participants in the campaign are invited to share their personal diabetes journeys with Glucerna, in order to gain the ...